A gene therapy (Luxturna) was approved in 2017 by the FDA for RPE65 mutation-associated retinal dystrophy in the treatment of Leber Congenital Amaurosis (LCA) by subretinal injection, but it is not based on RNA technologies. This evidence concerns the gene RPE65 and Leber congenital amaurosis.